Inside a pancreatic beta cell, the effect of a GLP-1 drug starts with a receptor on the surface and plays out within seconds. Understanding that sequence is the point of two recent review papers, one on beta cells and one on the liver. The same molecule, glucagon-like peptide-1, is made by intestinal L cells, and its receptors turn up across the body.
Seconds to minutes
The receptor couples with a G protein subunit called Gα s, which switches on an enzyme, adenylate cyclase, and sends levels of cyclic AMP climbing. According to a 2021 review in Frontiers in Endocrinology, cyclic AMP rises within seconds in beta cells and boosts glucose-stimulated insulin secretion within minutes. Two partners, Epac2 and protein kinase A, join in.
Epac2 lowers the ATP needed to shut KATP channels in the cell membrane. The membrane depolarises, calcium floods in, stored calcium is released, insulin granules are primed, and finally they are released. Protein kinase A pushes the same direction by chemically modifying the sulfonylurea receptor 1 and a regulatory part of those channels.
The effects reach beyond a single dose of insulin. The signalling raises insulin gene transcription and synthesis, and the review links it to beta cell survival, proliferation and the formation of new beta cells. PKA activates cyclin D1 and MAPK, which the authors describe as crucial for cells to move through the G1/S phase of division. The receptor also eases ER stress in beta cells. Those findings, the authors say, back the idea that sustained agonism could modify the course of type 2 diabetes by preserving working beta cell mass.
Not all receptors stay on the surface. Once activated, they are carried inside the cell, and the review notes that internalised receptors keep generating cyclic AMP, which contributes to insulin granule release. Agonists that favour one signalling route over another, a concept called biased agonism, are of growing interest because they could tune a drug’s effects.
Beyond blood sugar
A separate 2026 review in Frontiers in Pharmacology looked at the liver. It describes the drugs’ basic jobs: more insulin, less glucagon, slower emptying of the stomach, weight loss and a healthier cardiovascular system. It then turns to liver disease, cirrhosis, and conditions such as Alzheimer’s and Parkinson’s.
For the liver, the evidence points to anti-inflammatory action, changes to lipid metabolism and better survival of liver cells. In nonalcoholic steatohepatitis, the drugs appear to ease inflammation and boost insulin sensitivity, which improves how the liver handles glucose and reduces fat build-up. Much of this comes from animal work, where preclinical studies point to activation of the farnesoid X receptor and the liver X receptor, both important to lipid handling.
The authors are careful. They write that direct evidence of an anti-fibrotic effect is scant, and further experiments are needed.
Sources
- The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells (Frontiers in Endocrinology)
- The mechanisms of GLP-1 receptor agonists in liver disease (Frontiers in Pharmacology)
